Veracyte has announced that new data from the EMIT trial indicates the use of the Prosigna Breast Cancer Assay significantly changed treatment decisions for individuals diagnosed with early-stage breast cancer.

The study’s data demonstrated that the assay has also minimised the utilisation of chemotherapy in patients with clinically high-risk diseases.

The prospective, multi-year, population-based EMIT study in Norway is examining the impact of molecular testing, particularly the Prosigna test, on breast cancer care and outcomes.

The research conducted assessed a group of 2,164 women in Norway diagnosed with early-stage (node-negative) breast cancer.

The objective was to analyse the treatment decisions made by physicians for these patients before and after obtaining the results of a Prosigna test.

The researchers noticed that using Prosigna led to a change in adjuvant therapy decisions for nearly one-third (29%) of patients.

Prosigna examines the PAM50 gene signature activity and clinical-pathological features to offer a hormone-receptor-positive early breast cancer patient and their physician a prognostic score.

This score indicates the likelihood of cancer returning within the next ten years if the patient undergoes endocrine therapy alone.

The test can be conducted using the nCounter Analysis System and is accessible to laboratories in Europe and other regions.

Veracyte breast cancer medical director Kelly Marcom said: “We are honoured that the Prosigna test was selected to be part of EMIT, which we believe is among the most rigorous studies to evaluate the impact of gene expression testing on clinical decision-making and patient outcomes in breast cancer.”